Is There a Role for Beta-Blockers in Heart Failure Patients?

摘要: On initial reflection, consideration of beta-blockade in the therapy heart failure (HF) patients seems paradoxical. In most discussions therapeutics congestive failure, beta-blockers are listed as contraindicated, given their known negative inotropic potential. The general perception that contraindicated is adequately supported by clinical anecdotes, which administration beta-blocker (usually intravenously) with acute or subacute and medically uncompensated HF has led to dramatic adverse reactions such pulmonary edema low output syndrome hypotension shock. Thus, for would appear heretical based on conventional medical wisdom. Nevertheless, standard HF, while controlling symptoms short term, appears have had little impact dismal natural history disease (1–4). Given this poor prognosis, testing new unconventional approaches chronic appropriate. regard, it interest despite obvious danger administering intravenous full-dose beta-blocking drugs giving carefully titrated oral doses compensated, gaining increasing experimental support.